Estimating the rate of overdiagnosis with prostate cancer screening: evidence from the Finnish component of the European Randomized Study of Screening for Prostate Cancer

被引：0
作者：
S. D. Walter
Jiarui Hu
Kirsi Talala
Teuvo Tammela
Kimmo Taari
Anssi Auvinen
机构：
[1] McMaster University,Department of Health Research Methodology, Evidence, and Impact
[2] McMaster University,Department of Mathematics & Statistics
[3] Finnish Cancer Registry,Faculty of Medicine and Health Technology, and Tampere University Hospital
[4] Tampere University,Department of Urology, Helsinki University Hospital
[5] University of Helsinki,Faculty of Social Sciences
[6] Tampere University,undefined
来源：
Cancer Causes & Control | 2021年 / 32卷
关键词：
Prostate cancer; Screening; PSA; Randomized trial; Over-diagnosis; Mortality;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1299 / 1313
页数：14
相关论文
共 167 条
[1]  
Culp MB(2020)Recent global patterns in prostate cancer incidence and mortality rates Eur Urol 77 38-52
[2]  
Soerjomataram I(2018)Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial JAMA 319 883-895
[3]  
Efstathiou JA(2016)Trends in United States prostate cancer incidence rates by age and stage, 1995–2012 Cancer Epidemiol Biomar Prev 25 259-263
[4]  
Bray F(2019)A 16-yr follow-up of the European randomized study of screening for prostate cancer Eur Urol 76 43-51
[5]  
Jemal A(2018)EAU-ESTRO-ESUR-SIOG Guidelines on prostate cancer Eur Urol 73 e134-e135
[6]  
Martin RM(2009)Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context J Natl Cancer Inst 101 374-383
[7]  
Donovan JL(2013)Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening Ann Intern Med 158 831-111
[8]  
Turner EL(2003)MISCAN: estimating lead-time and over-detection by simulation BJUrol Int 92 106-2866
[9]  
Hoffman RM(2006)A population model of prostate cancer incidence Stat Med 25 2846-181
[10]  
Meisner ALW(2008)Quantifying the role of PSA screening in the US prostate cancer mortality decline Cancer Causes Control 19 175-1138
12345678910